1. Home
  2. In The News
  3. BioFactura’s Ustekinumab Biosimilar To Be Trialed As ‘Robotic’ Pill

Blog

BioFactura’s Ustekinumab Biosimilar To Be Trialed As ‘Robotic’ Pill

From Generics Bulletin/Informa Pharma Intelligence
By Dean Rudge 14SEP2021

BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill.

<Read Full Article>

September 14, 2021 In The News
About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *